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a b s t r a c t
Objective: Tolerance is a known consideration for maintenance use of benzodiazepines and other anti-
seizure drugs; however, clinical experience suggests that tolerance may not be anticipated with long-
term intermittent use of benzodiazepines as rescue therapy. Diazepam nasal spray (Valtoco) is a propri-
etary intranasal formulation approved for the acute treatment of intermittent, stereotypic episodes of fre-
quent seizure activity (ie, seizure clusters, acute repetitive seizures) in patients with epilepsy aged
6 years. Reported here are exploratory analyses investigating whether there was evidence of develop-
ment of tolerance in an interim analysis of a long-term, phase 3, open-label safety study of diazepam
nasal spray.
Methods: Patients and care partners were trained to administer 5, 10, 15, or 20 mg of diazepam nasal
spray (age- and weight-based dosing), with a second dose administered 4–12 hours later if needed. A ser-
ies of analyses were performed to assess evidence of tolerance using 2 equal, adjacent time periods and
data for each patient to compare the proportion of events for which second doses of diazepam nasal spray
(as a proxy for effectiveness) were administered in period 1 compared with period 2.
Results: A total of 175 patients were enrolled at interim cutoff, and 158 were treated with diazepam nasal
spray for 3370 seizure-cluster events. For 73.4% of patients, duration of exposure to diazepam nasal spray
was 12 months. A total of 191 analyses were conducted; the proportion of analyses in which second
doses in period 2 were lower than in period 1 was 72.8%. Only 5 analyses showed nominally statistically
significant changes (P < 0.05); this is fewer than expected by chance, and these differences were not
directionally consistent. There was no safety signal with continued use.
Conclusions: These analyses found no statistical evidence of tolerance with the use of diazepam nasal
spray over time based on use of a second dose in an initial period of the study compared with a subse-
quent period for each patient. These results are in agreement with prior studies of benzodiazepine rescue
therapy.
 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Reduced response to a drug after repeated administration (ie,
tolerance) is a known consideration for maintenance use of benzo-
diazepines and other antiseizure drugs [1,2]. Although tolerance is
https://doi.org/10.1016/j.yebeh.2021.107983
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typically associated with prolonged treatment and high doses of
antiseizure drugs [2], it may be associated with a number of other
factors, key of which are pharmacokinetic and pharmacodynamic
properties of the drug [1,2], as well as other factors that may occur
acutely. Tolerance may also vary with seizure type, even with the
same agent, as illustrated by studies of clobazam showing higher
levels of tolerance in patients with temporal lobe epilepsy (27%
at 1 year [3]) compared with Lennox-Gastaut syndrome (12% at
2 years [4]). Those studies defined tolerance as the development
of partial or complete loss of therapeutic effectiveness [3] or a
dosage increase 40% plus loss of response [4].
Benzodiazepines are the key treatment for seizure clusters [5–
7], also referred to as acute repetitive seizures, which are seizure
emergencies that contribute to the considerable burden of epilepsy
on affected patients and their care partners [8]. Seizure clusters are
associated with an increased risk of status epilepticus [9,10], hos-
pitalization [11], increased mortality [12], decreased quality of life,
and negative personal and financial impacts [8]. Seizure clusters
may occur at irregular intervals, so treatment must be readily
available for use as needed.
Given the importance of benzodiazepines in treatment of sei-
zure clusters, understanding tolerance in this role is important.
Clinical experience suggests that tolerance might not be antici-
pated with long-term intermittent use of benzodiazepines; inter-
mittent usage is one strategy to overcome or prevent tolerance
[2]. Although there are few formal analyses of tolerance in the
treatment of seizure clusters [13,14], they have not found evidence
of tolerance.
Diazepamnasal spray (Valtoco), a proprietary intranasal formu-
lation of diazepam approved by the US Food and Drug Administra-
tion for the acute treatment of intermittent, stereotypic episodes
of frequent seizure activity (ie, seizure clusters, acute repetitive sei-
zures) in patients with epilepsy aged 6 years, is designed to pro-
vide a rapid, noninvasive, and socially acceptable route of
administration. It is formulated with n-dodecyl-beta-D-maltoside
(Intravail A3), which is a nonionic surfactant used as a mucosal
absorption enhancement agent to promote increased bioavailability
[15] and vitamin E to enhance solubility of diazepam.
This exploratory analysis of a long-term, open-label safety study
of diazepam nasal spray investigated whether there was evidence
of development of tolerance. For this analysis, tolerance was based
on the proportion of events for which administration of a second
dose of diazepam nasal spray (as a proxy for effectiveness) was
administered for each patient in 2 time periods during the study.
2. Materials and methods
2.1. Study design
This was a long-term, open-label, repeat-dose safety study of
diazepam nasal spray in patients with epilepsy (NCT02721069).
The treatment period was 12 months, after which patients could
continue at the discretion of the Investigator. The investigators
conducted the study in accordance with the Declaration of Helsinki
and the International Conference on Harmonisation Good Clinical
Practice guidelines. The primary objective was to assess the safety
of diazepam nasal spray after repeated administration in patients
with epilepsy who experience frequent seizures. The study was
approved by local institutional review boards and written
informed consent was obtained for all patients.
2.2. Patients
The study enrolled male and female patients aged 6–65 years.
Patients were required to have a diagnosis of epilepsy and to be
experiencing frequent seizure episodes despite being on a stable
antiseizure-drug regimen and, in the opinion of the investigator,
may need benzodiazepine intervention for seizure control approx-
imately 1 time every other month (ie, for an average of 6 times a
year). Patients had either partial or generalized epilepsy with
motor seizures or seizures with clear alteration of awareness and
had a qualified care partner or medical professional available
who could administer study medication in the event of a seizure.
Other key inclusion criteria included absence of clinically signifi-
cant abnormal findings in medical history or on physical examina-
tion, electrocardiogram, clinical laboratory results during
screening, or any other condition that, in the opinion of the Inves-
tigator, would jeopardize the safety of the patient. Female patients
of childbearing potential agreed to use an approved method of
birth control. Current concomitant benzodiazepine (eg, clobazam)
use was permitted. Key exclusion criteria included history of major
depression or a past suicide attempt or suicidal ideation or a clin-
ically significant medical condition that would jeopardize the
safety of the patient.
2.3. Treatment and assessments
Care partners and patients were trained to administer diazepam
nasal spray. Doses were 5, 10, 15, or 20 mg based on patient age
and weight (Supplementary Table 1), and a second dose was to
be administered 4–12 h later if needed. Investigators could adjust
doses if a different dose was necessary per their medical judgment
and if there were no safety concerns associated with the dosing
change.
Patients and care partners recorded seizures and use of diaze-
pam nasal spray in diaries. Treatment-emergent adverse events
(TEAEs) were collected.
2.4. Analyses
Because the occurrence of seizure clusters varies naturally over
time and across individual patients—irrespective of treatment—a
series of analyses of tolerance was planned to investigate overall
trends across time of seizure-cluster response to diazepam nasal
spray and administration of a second dose.
For each of the analyses, tolerance was assessed by defining 2
equal, adjacent periods (period 1 [initial] and period 2 [subse-
quent]). Data for each patient were analyzed to compare the pro-
portion of events for which second doses were administered in
periods 1 and 2, then mean second-dose usage in each period
was calculated for all patients in that analysis. Two methods were
used to define ‘‘initial” and ‘‘subsequent”: (1) based on a minimum
number of events in both periods (eg, 10 seizure clusters in each)
and (2) based on a specific number of months (eg, 2 months in
each) in both periods.
For all methods, consideration was restricted to patients with
8 events in the initial period, and all feasible combinations of
time cutoffs and event cutoffs were considered. Seizure clusters
were defined as including any seizures within 24 h of the initial
event. The endpoint of interest was the proportion of events for
which there was a seizure cluster for each patient, averaged across
all patients in that specific analysis; this endpoint was assessed in
both period 1 (initial) and period 2 (subsequent), with hypothetical
examples illustrated in Table 1.
2.5. Statistics
For each of the analyses, the null hypothesis was that there is no
difference between the first and second periods with respect to the
proportion of events for which there was a seizure cluster, which
was assessed using 2-sided Wilcoxon signed rank tests.
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3. Results
As of October 31, 2019, the study had enrolled 175 patients; 158
received at least 1 dose of diazepam nasal spray, treating 3370
seizure-cluster events. Baseline characteristics are listed in Table 2.
3.1. Exposure to diazepam nasal spray
Overall, 11 (7.0%) patients had <6 months of exposure, 31
(19.6%) had 6 to <12 months of exposure, and 116 (73.4%) had
12 months of exposure. Median time on the study was
13.0 months (range, <1–36.6 months). Twenty-three (14.6%)
patients received a total of 1–2 doses during the study, 49
(31.0%) received 3–10 doses, 24 (15.2%) received 11–20 doses, 36
(22.8%) received 21–40 doses, and 26 (16.5%) received >40 doses.
There were 89 (56.3%) patients who used an average of 2 or more
doses per month. The retention rate was 83% in this long-term
study (47 patients completed the study and 84 were ongoing), with
27 patients discontinuing (lost to follow-up, n = 3; subject with-
drawal, n = 16; other, n = 8). For each dose group, retention of
ongoing patients as a function of study completion and discontin-
uations is shown in Fig. 1.
3.2. Measure of tolerance
Because the follow-up duration and patterns of usage varied
widely among patients, all feasible combinations of time cutoffs
and event cutoffs were considered for analysis. In total, 191 analy-
ses were conducted with time cutoffs from 2 to 15 months in each
period (totals of 4–30 months) and 1 to 18 events in each period
(totals of 2–36 events). Thus, a 6-month time cutoff required that
patients had two 6-month periods of data, for 12 months of data
in total. A brief summary of these results, displaying the maximum
number of events in each period, is shown in Table 3; all 191 anal-
yses are presented in Supplementary Table 2.
Across all analyses, the rate of second doses was generally lower
in period 2, with fewer second doses in period 2 in 139 (72.8%)
analyses and fewer second doses in period 1 in 52 (27.2%) analyses
(Fig. 2). For example, one high-use subgroup included patients
with at least 12 months of data and at least 18 events in each of
the two 6-month periods (Table 3, row 5). Among the 9 patients
meeting these time and event thresholds, the mean use of second
doses in the first period was 23%, whereas the second-period mean
for retreatment was 19.4%, a reduction in use over time of 3.6%
(P = 0.129). The mean lengths of first and second periods were sim-
ilar at 26.1 and 26.0 months, respectively.
Only 5 (2.6%) of these 191 analyses showed nominally statisti-
cally significant changes (P <0.05) between period 1 and period 2
Table 1
Hypothetical illustration of analyses using a 4-month cutoff, 8-event minimum example.
Period 1 (4 mo) Period 2 (4 mo) Difference
1 Dose only 2nd Dose used Proportion 1 Dose only 2nd Dose used Proportion
Patient A 8 1 12.5 7 0 0 12.5
Patient B 9 0 0 15 1 13.3 –13.3
Patient C 12 1 8.3 9 1 11.1 –2.8
Mean — — — — — — –0.6
Table 2
Demographic data, all patients (safety population).
Demographics Diazepam nasal spray
5 mg 10 mg 15 mg 20 mg Total
(n = 8) (n = 52) (n = 45) (n = 53) (n = 158)
Sex, n (%)
Male 2 (25.0) 27 (51.9) 15 (33.3) 29 (54.7) 73 (46.2)
Female 6 (75.0) 25 (48.1) 30 (66.7) 24 (45.3) 85 (53.8)
Age, y
Mean (SD) 9.6 (6.93) 12.1 (9.16) 27.6 (13.73) 33.4 (13.03) 23.5 (15.13)
Range 6–26 6–65 10–59 11–59 6–65
Race, n (%)
White 6 (75.0) 41 (78.8) 39 (86.7) 44 (83.0) 130 (82.3)
Black or African American 1 (12.5) 6 (11.5) 4 (8.9) 4 (7.5) 15 (9.5)
Asian 1 (12.5) 3 (5.8) 0 0 4 (2.5)
Native Hawaiian or Other Pacific Islanders 0 0 1 (2.2) 4 (7.5) 5 (3.2)
Other 0 2 (3.8) 1 (2.2) 1 (1.9) 4 (2.5)
Ethnicity
Hispanic or Latino 0 10 (19.2) 3 (6.7) 4 (7.5) 17 (10.8)
Non-Hispanic or Latino 8 (100.0) 42 (80.8) 42 (93.3) 49 (92.5) 141 (89.2)
Fig. 1. Study retention (Ongoing patients as of October 31, 2019). For each dose
group, retention of ongoing patients as a function of study completion (n = 47) and
discontinuations (n = 27) is shown; 84 patients ongoing.
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in number of second doses, fewer than expected by chance (ie, a
95% confidence for 191 analyses would suggest that 10 instances
would be expected to be nominally significant). Of the nominally
significant changes, the period 2 mean rate was greater than period
1 in 3 instances and smaller in 2 instances.
3.3. Safety profile
A total of 119 (75.3%) patients experienced TEAEs. The most
common nonseizure TEAEs (>5%) were nasopharyngitis (7.6%),
upper respiratory tract infection (7.6%), pneumonia (7.0%), pyrexia
(6.3%), and influenza (5.1%); no patients discontinued the study
owing to TEAEs. Twenty-six (16.5%) patients had TEAEs that were
considered at least possibly treatment related; of these, only nasal
discomfort (5.7%) occurred in >5% of patients. This was reported in
patients receiving 15 mg and 20 mg doses, which are given as 2
sprays, 1 in each nostril (ie, 7.5 mg  2 or 10 mg  2). Forty-five
(28.5%) patients experienced serious adverse events; none were
considered to be treatment related. There were no deaths recorded
by the cutoff date of this analysis. However, one death was
recorded after the cutoff date and was assessed as not being treat-
ment related.
4. Discussion
Although tolerance limits the use of benzodiazepines in contin-
uous therapy, intermittent use may eliminate or reduce the
chances that patients develop tolerance [2]. The results of our anal-
ysis found no statistical evidence of tolerance with the use of dia-
zepam nasal spray over time based on use of a second dose in an
initial period of the study compared with a subsequent period
for each patient. Across all analyses, the rate of second doses was
generally lower in period 2 compared with period 1.
Only 5 (2.5%) of the 191 analyses showed nominally statistically
significant changes (P < 0.05) between period 1 and period 2, fewer
than expected by chance. Notably, the nominally statistically sig-
nificant changes were not directionally consistent, with 3 increases
in period 2 relative to period 1 and 2 decreases in period 2 relative
to period 1.
This analysis is in agreement with prior studies of benzodi-
azepine rescue therapy. In an open-label extension trial, no toler-
ance was observed with long-term use of midazolam nasal spray
[14]. A total of 161 patients 12 years old with seizure clusters
were rolled over from a randomized controlled phase 3 trial to
the extension trial. In that study, a second dose was required in
797 of 1998 seizure episodes (39.9%). Tolerance was examined
by the number of second doses required relative to how many epi-
sodes had been treated for individual patients. No change was
observed in the proportion of patients requiring a second dose
based on number of treated episodes, to 50 episodes [14].
Similarly, no evidence of tolerance was observed in a long-term
study of diazepam rectal gel [13]. In that study, 149 patients, aged
2–76 years, from 1 of 2 randomized controlled trials enrolled into
an extension study. Extension patients recorded 1578 seizures,
and the effect of first and last dose was assessed for loss of efficacy.
The efficacy in terminating seizure clusters was similar for both
first and last administrations; 63% of patients had no subsequent
seizures after the first administration, and 69% had no subsequent
seizures after the last administration. Patients with low utilization
(2–7 treatments) compared with high utilization (8–78 treat-
ments) also showed similar levels of seizure control.
In the present study, safety was consistent with that of rectal
diazepam, and the retention rate was high, which suggests that
patients and care partners may have believed that the safety/effec-
tiveness profile was favorable. There were no reports of cardiac or
respiratory depression, no life-threatening adverse events, and no
discontinuations due to diazepam nasal spray.
This study has several considerations for interpretation. This
was an open-label design in which physicians were free to revise
Table 3
Mean percentage of events treated with second doses, averaged over patients, based on the cutoff with the highest number of events analyzed in each time period.
Month Cutoff Number of Events Cutoff Patients, n Period 1 Period 2 Difference, % (P2–P1) Events, n P Value*
Period 1 Period 2
Mean, % Mean, % Mean Max Mean Max
4 7 12 10.1 18.2 8.1 9.8 14 10.3 17 0.195
6 10 8 10.5 22.5 12.0 14.1 18 13.6 17 0.063
8 13 9 25.3 29.1 3.8 19.0 28 18.1 25 0.734
10 18 8 25.6 21.4 –4.2 24.4 32 23.1 38 0.195
12 18 9 23.0 19.4 –3.6 26.1 32 26.0 47 0.129
14 18 8 20.9 18.3 –2.6 27.6 36 29.0 53 0.547
16 17 8 13.6 12.3 –1.3 29.0 39 31.0 56 0.844
18 18 8 14.2 9.5 –4.7 32.5 52 34.4 64 0.156
20 18 8 16.8 14.9 –1.8 35.9 61 37.9 74 0.688
22 12 8 16.6 18.3 1.8 35.9 69 32.9 73 1.000
24 12 8 17.3 18.3 1.1 37.4 74 34.4 77 0.844
26 14 8 16.6 18.9 2.3 41.6 81 37.9 82 0.844
28 7 8 18.8 16.1 –2.6 39.5 82 41.8 99 0.375
30 9 8 18.6 16.5 –2.0 42.1 86 43.3 99 0.469
* Wilcoxon signed rank test.
Fig. 2. Proportions of scenarios with increased or decreased use of second doses in
period 1 compared with period 2.
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maintenance medications, and seizures and use of rescue was
monitored indirectly (via review of seizure diaries). Also, a clear
explanation for the lower numbers of second doses in period 2
compared with period 1 has not been identified. For example,
while it is possible that adverse events led to increasingly
restricted use of the study drug, the reported safety profile does
not support this interpretation. Strengths of the study include a
large patient population, number of seizures analyzed, and long
mean duration of treatment. The analysis of retreatment is robust
and shows consistent results for both calendar and event cutoffs.
Furthermore, there were a large number of analyses conducted,
which provides a detailed picture of retreatment over time. In con-
clusion, in this analysis of a long-term, open-label, repeat-dose
study, no tolerance was seen with intermittent repeat dosing of
diazepam nasal spray to control seizure clusters in patients with
epilepsy.
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